Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) shares hit a new 52-week low during trading on Monday . The stock traded as low as $11.01 and last traded at $11.28, with a volume of 312 shares trading hands. The stock had previously closed at $11.25.
Analyst Ratings Changes
Several research analysts have recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Citigroup decreased their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. JPMorgan Chase & Co. raised their price target on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a report on Thursday, March 20th. Scotiabank decreased their price objective on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. Finally, StockNews.com upgraded shares of Syndax Pharmaceuticals to a "sell" rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $36.20.
Check Out Our Latest Analysis on SNDX
Syndax Pharmaceuticals Price Performance
The firm has a market capitalization of $960.25 million, a PE ratio of -3.07 and a beta of 1.28. The company has a 50-day moving average price of $13.66 and a 200 day moving average price of $15.33.
Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.79). The company had revenue of $7.68 million during the quarter, compared to the consensus estimate of $86.32 million. As a group, research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.
Insider Activity at Syndax Pharmaceuticals
In related news, CEO Michael A. Metzger sold 13,288 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the completion of the sale, the chief executive officer now owns 300,121 shares in the company, valued at $4,651,875.50. This trade represents a 4.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Neil Gallagher sold 4,618 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $71,579.00. Following the transaction, the insider now directly owns 85,095 shares in the company, valued at approximately $1,318,972.50. This trade represents a 5.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,683 shares of company stock valued at $336,087 over the last 90 days. 4.10% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. R Squared Ltd bought a new stake in Syndax Pharmaceuticals during the 4th quarter valued at $26,000. Virtus ETF Advisers LLC raised its stake in shares of Syndax Pharmaceuticals by 18.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock worth $70,000 after acquiring an additional 827 shares in the last quarter. Cape Investment Advisory Inc. boosted its stake in Syndax Pharmaceuticals by 157.1% in the fourth quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company's stock valued at $85,000 after acquiring an additional 3,927 shares in the last quarter. KBC Group NV grew its holdings in Syndax Pharmaceuticals by 104.8% in the fourth quarter. KBC Group NV now owns 6,954 shares of the company's stock worth $92,000 after purchasing an additional 3,559 shares during the last quarter. Finally, Optimize Financial Inc acquired a new position in shares of Syndax Pharmaceuticals during the fourth quarter worth $152,000.
Syndax Pharmaceuticals Company Profile
(
Get Free Report)
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
Featured Stories
Before you consider Syndax Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.
While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
